Compare Globalstar (GSAT) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globalstar vs Organon & Co. Common Stock — how do they compare? Globalstar trades at $81.7 (market cap $10.71B), while Organon & Co. Common Stock trades at $13.73 (market cap $3.61B). The key difference: Globalstar is far larger — about 3× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Globalstar pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 23 Days and Organon & Co. Common Stock for 0 Days on average.
| GSAT | OGN | |
|---|---|---|
Market Cap | $10.71B | $3.61B |
Volume | 768,707 | 1,808,049 |
Sector | Media | Health |
52-Week High | $84.43 | $13.81 |
52-Week Low | $41.54 | $5.70 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | $10.71B | $11.03B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSAT trades at $82.68, down 0.43% with a bullish technical outlook. The company shows strong gross margins at 62.25% but faces profitability challenges with negative net income margins. Recent satellite launches and infrastructure expansion in Greece signal growth potential, though earnings have consistently missed expectations.
Investment outlook remains mixed with 40% analyst buy ratings but persistent losses. Key risks include execution challenges and high valuation multiples. Positive cash flow and strategic developments provide upside catalysts, but profitability improvement is critical for sustained shareholder value.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Globalstar
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
